Suppr超能文献

艾莱卡嗪是一种新型选择性心脏晚期钠电流抑制剂,在完整猪模型中可同时预防自主神经诱导的房性早搏、复极交替和复极离散以及房颤。

Eleclazine, a new selective cardiac late sodium current inhibitor, confers concurrent protection against autonomically induced atrial premature beats, repolarization alternans and heterogeneity, and atrial fibrillation in an intact porcine model.

作者信息

Fuller Henrique, Justo Fernanda, Nearing Bruce D, Kahlig Kristopher M, Rajamani Sridharan, Belardinelli Luiz, Verrier Richard L

机构信息

Beth Israel Deaconess Medical Center, Boston, Massachusetts; Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

Beth Israel Deaconess Medical Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

出版信息

Heart Rhythm. 2016 Aug;13(8):1679-86. doi: 10.1016/j.hrthm.2016.04.015. Epub 2016 Apr 21.

Abstract

BACKGROUND

The cardiac late sodium current (INa) has been increasingly implicated in the initiation of atrial fibrillation (AF). Eleclazine (formerly known as GS-6615) is a new selective late INa inhibitor and is undergoing clinical testing for the treatment of cardiac arrhythmias.

OBJECTIVE

We tested whether late INa inhibition by eleclazine confers protection against atrial premature beats (APBs) and AF.

METHODS

In closed-chest anesthetized Yorkshire pigs, epinephrine (2.0 µg/kg, intravenous, bolus over 1 minute) was administered alone to induce APBs (n = 6) or in combination with intrapericardial acetylcholine (0.5-4 mL of 12.5 mM solution) to induce spontaneous AF (n = 11). Effects of eleclazine (0.3 and 0.9 mg/kg, intravenous, over 15 minutes) on APBs and AF were determined.

RESULTS

Epinephrine-induced APBs were reduced >3-fold (P < .04) after eleclazine (0.9 mg/kg) infusion. The combined administration of epinephrine and acetylcholine resulted in AF in all animals tested, which was invariably preceded by APBs. Eleclazine pretreatment suppressed AF in all 7 animals in at least 1 test episode during the 60- to 150-minute observation period (P = .04). The plasma eleclazine level at 120 minutes was 828 ± 45.8 nM, within exposure range evaluated clinically. Eleclazine shortened ventricular QT and atrial PTa intervals by 7% (P < .001 for both) and reduced atrial repolarization alternans (P = .003) and heterogeneity (P = .021) without attenuation of the inotropic response to catecholamine (P = .56). The drug inhibited the enhanced late INa of single atrial myocytes with a potency of 736 ± 67 nM.

CONCLUSION

Selective cardiac late INa inhibition with eleclazine suppresses autonomically mediated atrial repolarization alternans and heterogeneity, APBs, and AF in an intact porcine model.

摘要

背景

心脏晚钠电流(INa)越来越多地被认为与房颤(AF)的发生有关。依来卡嗪(以前称为GS - 6615)是一种新型选择性晚钠电流抑制剂,正在进行治疗心律失常的临床试验。

目的

我们测试了依来卡嗪对晚钠电流的抑制是否能预防房性早搏(APB)和房颤。

方法

在开胸麻醉的约克夏猪中,单独给予肾上腺素(2.0μg/kg,静脉注射,1分钟内推注)以诱导房性早搏(n = 6),或与心包内乙酰胆碱(0.5 - 4 mL的12.5 mM溶液)联合使用以诱导自发性房颤(n = 11)。测定依来卡嗪(0.3和0.9 mg/kg,静脉注射,15分钟以上)对房性早搏和房颤的影响。

结果

输注依来卡嗪(0.9 mg/kg)后,肾上腺素诱导的房性早搏减少了3倍以上(P <.04)。肾上腺素和乙酰胆碱联合给药在所有受试动物中均导致房颤,且房颤总是先于房性早搏出现。依来卡嗪预处理在60至150分钟观察期内的至少1次测试发作中抑制了所有7只动物的房颤(P =.04)。120分钟时血浆依来卡嗪水平为828±45.8 nM,在临床评估的暴露范围内。依来卡嗪使心室QT和心房PTa间期缩短7%(两者P <.001),并减少心房复极交替(P =.003)和异质性(P =.021),而不减弱对儿茶酚胺的变力反应(P =.56)。该药物抑制单个心房肌细胞增强的晚钠电流,效力为736±67 nM。

结论

在完整的猪模型中,依来卡嗪选择性抑制心脏晚钠电流可抑制自主神经介导的心房复极交替和异质性、房性早搏及房颤。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验